A detailed history of Northern Trust Corp transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Northern Trust Corp holds 46,852 shares of XENE stock, worth $1.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,852
Previous 48,470 3.34%
Holding current value
$1.81 Million
Previous $2.09 Million 12.46%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$36.25 - $43.75 $58,652 - $70,787
-1,618 Reduced 3.34%
46,852 $1.83 Million
Q1 2024

May 14, 2024

SELL
$42.66 - $50.04 $575,952 - $675,590
-13,501 Reduced 21.79%
48,470 $2.09 Million
Q4 2023

Feb 13, 2024

SELL
$28.7 - $46.46 $206,525 - $334,326
-7,196 Reduced 10.4%
61,971 $2.85 Million
Q3 2023

Nov 13, 2023

BUY
$34.16 - $39.73 $125,845 - $146,365
3,684 Added 5.63%
69,167 $2.36 Million
Q2 2023

Aug 11, 2023

BUY
$34.84 - $43.54 $156,083 - $195,059
4,480 Added 7.34%
65,483 $2.52 Million
Q1 2023

May 15, 2023

BUY
$33.46 - $40.35 $26,299 - $31,715
786 Added 1.31%
61,003 $2.18 Million
Q4 2022

Feb 13, 2023

BUY
$33.06 - $39.43 $308,317 - $367,724
9,326 Added 18.33%
60,217 $2.37 Million
Q3 2022

Nov 14, 2022

BUY
$30.79 - $39.82 $89,137 - $115,278
2,895 Added 6.03%
50,891 $1.84 Million
Q2 2022

Aug 12, 2022

BUY
$25.44 - $35.16 $81,916 - $113,215
3,220 Added 7.19%
47,996 $1.46 Million
Q1 2022

May 13, 2022

SELL
$25.09 - $33.13 $146,023 - $192,816
-5,820 Reduced 11.5%
44,776 $1.37 Million
Q4 2021

Feb 08, 2022

BUY
$15.6 - $35.4 $198,837 - $451,208
12,746 Added 33.68%
50,596 $1.58 Million
Q3 2021

Nov 15, 2021

SELL
$14.86 - $19.45 $102,103 - $133,640
-6,871 Reduced 15.36%
37,850 $579,000
Q2 2021

Aug 13, 2021

SELL
$16.81 - $20.0 $98,187 - $116,820
-5,841 Reduced 11.55%
44,721 $832,000
Q1 2021

May 12, 2021

BUY
$13.65 - $21.31 $53,781 - $83,961
3,940 Added 8.45%
50,562 $904,000
Q4 2020

Feb 11, 2021

SELL
$9.49 - $16.04 $149,287 - $252,325
-15,731 Reduced 25.23%
46,622 $717,000
Q3 2020

Nov 16, 2020

BUY
$10.82 - $13.35 $7,768 - $9,585
718 Added 1.16%
62,353 $690,000
Q2 2020

Aug 14, 2020

BUY
$10.21 - $14.9 $30,997 - $45,236
3,036 Added 5.18%
61,635 $772,000
Q1 2020

May 14, 2020

BUY
$8.08 - $17.57 $116,804 - $253,991
14,456 Added 32.75%
58,599 $664,000
Q4 2019

Feb 14, 2020

BUY
$8.11 - $14.65 $52,771 - $95,327
6,507 Added 17.29%
44,143 $579,000
Q2 2019

Aug 13, 2019

BUY
$8.51 - $10.75 $114,323 - $144,415
13,434 Added 55.51%
37,636 $371,000
Q1 2019

May 13, 2019

BUY
$6.39 - $10.42 $76,398 - $124,581
11,956 Added 97.63%
24,202 $246,000
Q4 2018

Feb 12, 2019

BUY
$5.61 - $12.62 $10,928 - $24,583
1,948 Added 18.92%
12,246 $77,000
Q3 2018

Nov 14, 2018

BUY
$9.0 - $14.9 $92,682 - $153,440
10,298 New
10,298 $136,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.41B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.